Some other changes, such as the downregulation of p-glycoprotein (it is the so-called MDR—Multi Drug Resistance protein, which increases the drugs’ efflux out of the cells) [85,87] and drug metabolizing enzyme ALDH3A1 ensued, which opens up new possibilities in the management of breast cancer drug-resistance issue [88]. This evidence concerns the gene ALDH3A1 and breast carcinoma.